Shanghai RAAS Blood Products Co Ltd Class A (002252) — Net Asset Quality Index
Shanghai RAAS Blood Products Co Ltd Class A (002252) has a Net Asset Quality Index of 85.6% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥37.98 Billion minus total liabilities of CN¥5.46 Billion yields net assets of CN¥32.52 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check Shanghai RAAS Blood Products Co Ltd Clas liquidity resilience to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Shanghai RAAS Blood Products Co Ltd Class A Net Asset Quality Index Over Time (2005–2025)
This chart shows how Shanghai RAAS Blood Products Co Ltd Class A's Net Asset Quality Index has evolved across 21 annual periods from 2005 to 2025. As of March 2026, the index stands at 85.6%, representing net assets of CN¥32.52 Billion against total assets of CN¥37.98 Billion CNY. See how liquid is Shanghai RAAS Blood Products Co Ltd Clas's working capital to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Shanghai RAAS Blood Products Co Ltd Class A (2005–2025)
The table below presents the year-by-year Net Asset Quality Index for Shanghai RAAS Blood Products Co Ltd Class A from 2005 to 2025, covering 21 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see 002252 market cap.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 85.9% | CN¥32.47 Billion | CN¥37.80 Billion | CN¥5.34 Billion | ▼ -9.1 pp |
| 2024 | 95.0% | CN¥31.94 Billion | CN¥33.63 Billion | CN¥1.69 Billion | ▲ +2.1 pp |
| 2023 | 92.9% | CN¥29.65 Billion | CN¥31.93 Billion | CN¥2.28 Billion | ▼ -1.7 pp |
| 2022 | 94.6% | CN¥28.81 Billion | CN¥30.46 Billion | CN¥1.64 Billion | ▼ -0.5 pp |
| 2021 | 95.1% | CN¥25.90 Billion | CN¥27.24 Billion | CN¥1.33 Billion | ▼ -3.5 pp |
| 2020 | 98.6% | CN¥25.13 Billion | CN¥25.49 Billion | CN¥363.74 Million | ▲ +1.6 pp |
| 2019 | 96.9% | CN¥11.49 Billion | CN¥11.85 Billion | CN¥361.95 Million | ▲ +1.3 pp |
| 2018 | 95.6% | CN¥10.90 Billion | CN¥11.40 Billion | CN¥496.56 Million | ▲ +9.3 pp |
| 2017 | 86.3% | CN¥12.48 Billion | CN¥14.46 Billion | CN¥1.98 Billion | ▼ -2.4 pp |
| 2016 | 88.7% | CN¥11.73 Billion | CN¥13.23 Billion | CN¥1.50 Billion | ▼ -4.0 pp |
| 2015 | 92.7% | CN¥10.71 Billion | CN¥11.56 Billion | CN¥843.64 Million | ▲ +0.8 pp |
| 2014 | 91.9% | CN¥8.62 Billion | CN¥9.38 Billion | CN¥755.16 Million | ▲ +22.0 pp |
| 2013 | 69.9% | CN¥1.10 Billion | CN¥1.58 Billion | CN¥473.37 Million | ▼ -14.4 pp |
| 2012 | 84.4% | CN¥1.02 Billion | CN¥1.21 Billion | CN¥188.79 Million | ▼ -7.5 pp |
| 2011 | 91.9% | CN¥927.27 Million | CN¥1.01 Billion | CN¥82.26 Million | ▲ +2.5 pp |
| 2010 | 89.3% | CN¥831.21 Million | CN¥930.33 Million | CN¥99.12 Million | ▼ -3.2 pp |
| 2009 | 92.5% | CN¥763.33 Million | CN¥825.22 Million | CN¥61.88 Million | ▲ +1.7 pp |
| 2008 | 90.8% | CN¥754.76 Million | CN¥831.19 Million | CN¥76.42 Million | ▲ +35.3 pp |
| 2007 | 55.5% | CN¥170.01 Million | CN¥306.54 Million | CN¥136.53 Million | ▲ +7.2 pp |
| 2006 | 48.2% | CN¥156.77 Million | CN¥325.16 Million | CN¥168.39 Million | ▼ -21.2 pp |
| 2005 | 69.4% | CN¥231.70 Million | CN¥333.63 Million | CN¥101.93 Million | — |